Nova22038
Eye inflammation is linked to several conditions such as conjunctivitis, anterior uveitis, keratitis, etc... It is also a consequence of post-cataract eye surgery. Main symptoms are eye redness and pain.
Ophthalmologists increasingly embrace the value of topical NSAIDs, in combination or instead of corticosteroids, and use them more routinely to increase patient comfort after ocular surgery as well as to reduce the incidence of cystoid macular edema, which is the most common sight-threatening complication after cataract surgery.
Nova22038 is an innovative formulation of a non steroidal anti-inflammatory drug. The product is intended for postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction. Nova22038 reduces the number of daily instillations thanks to the Novasorb® cationic emulsion. It has been demonstrated that a simplified dosing regimen improves compliance, a critical aspect for achieving optimal efficacy of treatments.